Regardless of which version you use, the starting principle is the same: begin low and escalate gradually
The purpose of this study was to evaluate the risk of cardiovascular events of GLP-1 (albiglutide, exenatide, liraglutide, semaglutide, lixisenatide and dulaglutide) receptor agonists in T2DM patients
SGLT2 inhibitors (sodium-glucose co-transporter-2 inhibitors) represent an excellent alternative class: Medications such as empagliflozin, dapagliflozin, or canagliflozin work by increasing urinary glucose excretion
But I don't need to do that
We recommend taking 0.1ml (a tenth of your syringe) each night before bed
The current Certificate of Analysis is stored in our COA Library, where results are readily available for review